{"id":63807,"date":"2026-04-23T21:36:55","date_gmt":"2026-04-23T13:36:55","guid":{"rendered":"https:\/\/flcube.com\/?p=63807"},"modified":"2026-04-23T21:36:57","modified_gmt":"2026-04-23T13:36:57","slug":"fda-extends-review-timeline-for-sanofis-sarclisa-subcutaneous-formulation-by-three-months-new-decision-date-set-for-july-23-2026","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63807","title":{"rendered":"FDA Extends Review Timeline for Sanofi&#8217;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026"},"content":{"rendered":"\n<p>The <strong>U.S. Food and Drug Administration (FDA)<\/strong> has extended the target action date for its review of <strong>Sanofi (<a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ: SNY<\/a>)&#8217;s biologics license application<\/strong> for <strong>Sarclisa (isatuximab-irfc) subcutaneous (SC)<\/strong> formulation by up to three months. The revised decision date is now <strong>July 23, 2026<\/strong>. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with <strong>multiple myeloma (MM)<\/strong> across all currently approved U.S. indications of the intravenous (IV) formulation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-summary\">Regulatory Timeline Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Action Type<\/strong><\/td><td>Review timeline extension<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sarclisa (isatuximab-irfc) subcutaneous (SC)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Multiple myeloma (all current IV formulation indications)<\/td><\/tr><tr><td><strong>Original Target Date<\/strong><\/td><td>April 22, 2026<\/td><\/tr><tr><td><strong>Revised Target Date<\/strong><\/td><td>July 23, 2026<\/td><\/tr><tr><td><strong>Extension Period<\/strong><\/td><td>Up to three months<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Final FDA decision expected by July 23, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-global-status\">Product Profile &amp; Global Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Approval:<\/strong> Sarclisa IV is approved in nearly <strong>60 countries<\/strong> across <strong>four indications<\/strong> for certain patients with newly diagnosed MM and relapsed or refractory MM<\/li>\n\n\n\n<li><strong>New Formulation:<\/strong> Sarclisa SC can be administered via both <strong>on-body injector (OBI)<\/strong> and <strong>manual injection<\/strong>, offering improved convenience over IV infusion<\/li>\n\n\n\n<li><strong>European Status:<\/strong> Received <strong>positive opinion<\/strong> from the <strong>European Medicines Agency Committee for Medicinal Products for Human Use (CHMP)<\/strong> on <strong>March 26, 2026<\/strong><\/li>\n\n\n\n<li><strong>EU Timeline:<\/strong> Final European Commission decision expected in the coming months<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Subcutaneous administration reduces treatment time from hours (IV) to minutes (SC), improving patient experience and clinic workflow<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Opportunity<\/strong><\/td><td>U.S. multiple myeloma market valued at $8.2 billion annually with ~35,000 new cases yearly<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>Direct competition with other anti-CD38 monoclonal antibodies; SC formulation represents significant differentiation<\/td><\/tr><tr><td><strong>Revenue Impact<\/strong><\/td><td>Sanofi projects peak annual sales of $1.8\u20132.2 billion for SC formulation if approved<\/td><\/tr><tr><td><strong>Patient Benefit<\/strong><\/td><td>SC administration reduces clinic visit duration from 4\u20136 hours (IV) to 5\u201310 minutes (SC injection)<\/td><\/tr><tr><td><strong>Commercial Readiness<\/strong><\/td><td>Sanofi has indicated commercial launch readiness within 30 days of approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>The three-month extension suggests the FDA may require additional information or analysis, though such extensions are not uncommon for complex biologics applications. Importantly, the agency did not indicate any safety concerns or clinical hold, which would have been communicated separately.<\/p>\n\n\n\n<p>For Sanofi, the Sarclisa SC formulation represents a critical strategic asset in maintaining market leadership in the multiple myeloma space. The subcutaneous delivery method addresses key patient and provider pain points associated with lengthy IV infusions, potentially improving treatment adherence and quality of life.<\/p>\n\n\n\n<p>The positive CHMP opinion in Europe provides regulatory validation of the SC formulation&#8217;s safety and efficacy profile, strengthening the case for U.S. approval. Sanofi&#8217;s global strategy appears well-coordinated, with near-simultaneous regulatory submissions in major markets.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines, market opportunities, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has extended the target action date for its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63808,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[38,867,147],"class_list":["post-63807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-nasdaq-sny","tag-sanofi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Extends Review Timeline for Sanofi&#039;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)&#039;s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63807\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Extends Review Timeline for Sanofi&#039;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)&#039;s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63807\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-23T13:36:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-23T13:36:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Extends Review Timeline for Sanofi&#8217;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026\",\"datePublished\":\"2026-04-23T13:36:55+00:00\",\"dateModified\":\"2026-04-23T13:36:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2301.webp\",\"keywords\":[\"Market approval filings\",\"NASDAQ: SNY\",\"Sanofi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63807#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63807\",\"name\":\"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2301.webp\",\"datePublished\":\"2026-04-23T13:36:55+00:00\",\"dateModified\":\"2026-04-23T13:36:57+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)'s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63807\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/2301.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63807#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Extends Review Timeline for Sanofi&#8217;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026 - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)'s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63807","og_locale":"en_US","og_type":"article","og_title":"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026","og_description":"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)'s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.","og_url":"https:\/\/flcube.com\/?p=63807","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-23T13:36:55+00:00","article_modified_time":"2026-04-23T13:36:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63807#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63807"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Extends Review Timeline for Sanofi&#8217;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026","datePublished":"2026-04-23T13:36:55+00:00","dateModified":"2026-04-23T13:36:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63807"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63807#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","keywords":["Market approval filings","NASDAQ: SNY","Sanofi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63807#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63807","url":"https:\/\/flcube.com\/?p=63807","name":"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63807#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63807#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","datePublished":"2026-04-23T13:36:55+00:00","dateModified":"2026-04-23T13:36:57+00:00","description":"The U.S. Food and Drug Administration (FDA) has extended the target action date for its review of Sanofi (NASDAQ: SNY)'s biologics license application for Sarclisa (isatuximab-irfc) subcutaneous (SC) formulation by up to three months. The revised decision date is now July 23, 2026. The application seeks approval for Sarclisa SC in combination with approved standard-of-care regimens for treating patients with multiple myeloma (MM) across all currently approved U.S. indications of the intravenous (IV) formulation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63807#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63807"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63807#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","width":1080,"height":608,"caption":"FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63807#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Extends Review Timeline for Sanofi&#8217;s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63807"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63807\/revisions"}],"predecessor-version":[{"id":63809,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63807\/revisions\/63809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63808"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}